Substance-related Disorders
Conditions
Keywords
Mindfulness, Women, Relapse prevention, Clinical trial, Substance use disorder, Ethnically diverse, Underserved, Health disparities, Stress, Addiction, Latina/Hispanic, African American, Treatment retention, Residential treatment, Brain Imaging
Brief summary
Approximately 25 million Americans struggle with alcohol or drug problems annually. Abuse of alcohol and drugs is costly to our nation, exacting more than $428 billion in costs related to crime, lost work productivity and health care. While effective treatments exist, over half of those who enter treatment for substance use disorders drop out early in treatment and return to alcohol or drug abuse. Psychological stress is a causal factor in the pathogenesis of substance use disorder (SUD) and relapse risk. Low-income women report high levels of stress in SUD residential treatment stemming from significant economic and family stressors in addition to challenges of adjusting to residential treatment demands. Unmanaged stress, especially in early stages of residential treatment, is a major concern because it can increase dropout. Dropout from residential treatment places women at risk of substance use relapse. A gap in knowledge persists regarding the use of mindfulness-based interventions with racially/ethnically diverse low-income women with SUDs, especially regarding the efficacy of adapted (Mindfulness-based interventions) MBIs for preventing residential dropout and decreasing relapse. We have fully adapted, developed, and pilot tested a novel MBI, Moment-by-Moment in Women's Recovery: Mindfulness Based Relapse Prevention for Women (MBRP-W), that supports the needs of women in residential treatment. This MBI integrates relapse prevention, addresses literacy level, and is relevant to issues surrounding treatment- and relapse-related stressors of disadvantaged women. The current project has three specific aims: (1) to test the efficacy of MBRP-W on residential treatment retention and substance use relapse in racially/ethnically diverse low-income women; (2) to determine the mechanisms of change underlying the MBRP-W program; and (3) to explore neural changes associated with program effects. A rationale for MBRP-W is the need for self-initiated stress management skills in women with SUDs during the early stressful periods of residential treatment that increase risk of dropout and relapse.
Detailed description
* This randomized clinical trial will deliver two interventions as add-ons to residential substance use disorder (SUD) treatment: (1) Moment-by-Moment in women's Recovery: Mindfulness-Based Approach to Relapse Prevention (MBRP-W) and (2) Brain and Recovery (B&R) which serves as an active psychoeducational attention control group. * Participants (N=165) who meet study eligibility criteria based on intake assessment will be recruited and complete baseline assessments during weeks 3-6 after entry into a residential treatment program. Participants will be randomly assigned to interventions using Urn randomization. All participants (MBRP-W and B&R) will receive SUD treatment as normally provided by the treatment program. Fifteen participants from each intervention group (N=30) will be selected to participate in a brain imaging (MRI and fMRI) substudy. * Participants will be adult females who have been admitted to a residential treatment center in an urban area of California and who are diagnosed with a SUD based on clinical intake Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) diagnostic assessment. * MBRP-W is delivered in 12 bi-weekly 80-minute group sessions with SUD clinical populations. Facilitators will have previous experience in MBSR facilitation and will be trained in MBRP-W. Each session has a central theme and is divided into five segments consisting of (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and practice assignments for the next class. * B&R is delivered in 12 bi-weekly 80-minute group sessions with SUD clinical populations. Facilitators will be trained in B&R. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, relapse prevention, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to that of the current study (i.e., racially/ethnically diverse and low-income women in SUD treatment) with input and review from focus group participants, care providers in SUD treatment, and three experts on the neurobiology of addiction. Topics include: (1) brain structure and function related to addiction, (2) effects of various types of substance use on the brain, and (3) rewarding effects of substance use and how these rewarding effects can lead to addiction. * There are three data collection points, 1) baseline, 2) immediate post-intervention, and 3) 8-months post-intervention completion. Data will be collected in-person by research interviewers via computer-assisted interviews, which includes administration of an alcohol Breathalyzer test to assess alcohol use and collection of a urine sample to assess drug use. Interviews will be conducted at the treatment program (for those who remain in residential treatment) or at convenient locations for participants no longer in treatment. Baseline interview will occur prior to randomization, post-intervention interview will occur within 1-2 weeks of the last group session, and the follow-up interview will occur at an 8-months post-intervention completion window. Brain imaging for a subsample of participants will be completed at baseline and immediate post-intervention. * Number of intervention program class sessions attended will be collected for all enrolled participants. * Participant Satisfaction Surveys measuring acceptability, credibility, and perceived utility of the study arms will be administered to both groups at two class sessions. * Applied Mindfulness Practice Scale (AMPS) measuring the participant's application of mindfulness skills to address life challenges, will be administered to the MBRP-W participants at four class sessions as well as at follow-up. Mindfulness practice effort will also be assessed at these same four class sessions. * An in-treatment clinical record review of services will be collected weekly for the duration of residential treatment.
Interventions
MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
Sponsors
Study design
Eligibility
Inclusion criteria
for parent study: * Female * Adult in California (18 years or older) * Diagnosed with a substance use disorder (SUD) * Speaks fluent English * Client at study site, substance use disorder residential facility at time of recruitment
Exclusion criteria
for parent study: * Inability to comprehend informed consent * Unwilling to sign informed consent * Cognitive impairment, psychotic disorder or severe chronic mental health condition based on clinical intake DSM-V assessment * Older than 65 years of age * Reported suicidality in last 30 days * Current prisoner * Pregnant in the 3rd trimester * Pregnant (MRI subsample only) * Not willing to be audio recorded * Not willing to have data stored for research purposes Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Completion | 5 month follow period | Number of women being designated by the site clinic as a completer during a discharge event. |
| Days of Any Drug Use | 8.5 months | Days of any drug use to include multiple drug types from study intervention end date to follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Psychological Symptoms | 8.5 months | Five Facet Mindfulness Questionnaire (FFMQ): higher scores indicate better mindfulness qualities (better outcome). Perceived Stress Scale (PSS): higher scores indicate greater perceived stress (worse outcome). Depression Anxiety Stress Scale (DASS): higher scores indicate greater depression, anxiety, and stress (worse outcome). Distress Tolerance Scale (DTS): higher scores indicate greater distress tolerance (better outcome). Difficulties in Emotion Regulation Scale (DERS): higher scores indicate greater difficulties in emotion regulation (worse outcome). Penn Craving Scale (PCS): higher scores indicate greater craving (worse outcome). Positive and Negative Affect Schedule (PANAS) - Negative Affect subscale: higher scores indicate greater negative affect (worse outcome). Minimum and maximum values are not standardized. |
Countries
United States
Participant flow
Recruitment details
Participants were adult women clinically diagnosed with SUD and admitted to residential SUD treatment. Recruitment spanned 2015-2018. All patients met one-on-one with the site's intake clinician coordinator. The site psychiatrist and on-site clinician coordinator discussed diagnostic assessment, determined final diagnoses, and made record in the patient chart. The site intake counselor verified study eligibility, and for those women who were eligible, informed clients about our study.
Pre-assignment details
Of 367 potential participants who were screened for the study at the residential site, 200 were eligible and randomized to study conditions and attended the first treatment sessions. Those who missed the first study class session (class overview and introduction) were excluded from the study by design leaving N = 200 enrolled in the trial, 100 per condition.
Participants by arm
| Arm | Count |
|---|---|
| Mindfulness Meditation [100 Enrolled] Mindfulness-Based Relapse Prevention-Women (MBRP-W)
Mindfulness Meditation: MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program. | 100 |
| Active Comparator [100 Enrolled] Brain and Recovery (B&R)
Brain and Recovery (B&R): B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain. | 100 |
| Total | 200 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 13 | 7 |
Baseline characteristics
| Characteristic | Mindfulness Meditation [100 Enrolled] | Active Comparator [100 Enrolled] | Total |
|---|---|---|---|
| Age, Continuous | 32.4 years STANDARD_DEVIATION 9.8 | 32.6 years STANDARD_DEVIATION 8.4 | 32.5 years STANDARD_DEVIATION 9.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 56 Participants | 60 Participants | 116 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 43 Participants | 38 Participants | 81 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 3 Participants |
| Region of Enrollment United States | 100 participants | 100 participants | 200 participants |
| Sex: Female, Male Female | 100 Participants | 100 Participants | 200 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| SUD diagnosis DSM5 Alcohol use disorder | 10 participants | 9 participants | 19 participants |
| SUD diagnosis DSM5 Both disorders | 18 participants | 14 participants | 32 participants |
| SUD diagnosis DSM5 Drug use disorder | 71 participants | 74 participants | 145 participants |
| SUD diagnosis DSM5 Missing | 1 participants | 3 participants | 4 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 100 | 0 / 100 |
| other Total, other adverse events | 0 / 100 | 0 / 100 |
| serious Total, serious adverse events | 0 / 100 | 0 / 100 |
Outcome results
Days of Any Drug Use
Days of any drug use to include multiple drug types from study intervention end date to follow-up
Time frame: 8.5 months
Population: Women with SUD enrolled in a residential treatment program who remained in the study and completed follow-up assessments approximately 8.5 months after the start of the intervention.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mindfulness Meditation | Days of Any Drug Use | 16.92 days | Standard Deviation 32.81 |
| Active Comparator | Days of Any Drug Use | 24.97 days | Standard Deviation 51.65 |
Treatment Completion
Number of women being designated by the site clinic as a completer during a discharge event.
Time frame: 5 month follow period
Population: Women with SUD at a residential treatment site
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mindfulness Meditation | Treatment Completion | 43 Number of women |
| Active Comparator | Treatment Completion | 31 Number of women |
Psychological Symptoms
Five Facet Mindfulness Questionnaire (FFMQ): higher scores indicate better mindfulness qualities (better outcome). Perceived Stress Scale (PSS): higher scores indicate greater perceived stress (worse outcome). Depression Anxiety Stress Scale (DASS): higher scores indicate greater depression, anxiety, and stress (worse outcome). Distress Tolerance Scale (DTS): higher scores indicate greater distress tolerance (better outcome). Difficulties in Emotion Regulation Scale (DERS): higher scores indicate greater difficulties in emotion regulation (worse outcome). Penn Craving Scale (PCS): higher scores indicate greater craving (worse outcome). Positive and Negative Affect Schedule (PANAS) - Negative Affect subscale: higher scores indicate greater negative affect (worse outcome). Minimum and maximum values are not standardized.
Time frame: 8.5 months
Population: Women with SUD
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mindfulness Meditation | Psychological Symptoms | Depression Anxiety Stress Scale (high worse; range 0-63) | 9 score on a non-standardized scale | Standard Deviation 0.6 |
| Mindfulness Meditation | Psychological Symptoms | Difficulties in emotion regulation scale (high worse, range 7-126) | 74 score on a non-standardized scale | Standard Deviation 2.4 |
| Mindfulness Meditation | Psychological Symptoms | Perceived Stress Scale (high worse; range 0-40) | 18 score on a non-standardized scale | Standard Deviation 0.7 |
| Mindfulness Meditation | Psychological Symptoms | Penn Alcohol Craving Scale (high worse, range 1-7) | 1.6 score on a non-standardized scale | Standard Deviation 0.2 |
| Mindfulness Meditation | Psychological Symptoms | Distress Tolerance Scale (high better; range 1-5) | 3.3 score on a non-standardized scale | Standard Deviation 0.1 |
| Mindfulness Meditation | Psychological Symptoms | Negative Affect Subscale (high worse, range 10-50) | 23 score on a non-standardized scale | Standard Deviation 0.8 |
| Mindfulness Meditation | Psychological Symptoms | Five Facet Mindfulness Questionnaire (high better; range 5-195) | 83 score on a non-standardized scale | Standard Deviation 1.3 |
| Active Comparator | Psychological Symptoms | Negative Affect Subscale (high worse, range 10-50) | 23 score on a non-standardized scale | Standard Deviation 0.8 |
| Active Comparator | Psychological Symptoms | Five Facet Mindfulness Questionnaire (high better; range 5-195) | 85 score on a non-standardized scale | Standard Deviation 1.2 |
| Active Comparator | Psychological Symptoms | Perceived Stress Scale (high worse; range 0-40) | 17 score on a non-standardized scale | Standard Deviation 0.06 |
| Active Comparator | Psychological Symptoms | Depression Anxiety Stress Scale (high worse; range 0-63) | 9 score on a non-standardized scale | Standard Deviation 0.6 |
| Active Comparator | Psychological Symptoms | Distress Tolerance Scale (high better; range 1-5) | 3.2 score on a non-standardized scale | Standard Deviation 0.1 |
| Active Comparator | Psychological Symptoms | Difficulties in emotion regulation scale (high worse, range 7-126) | 74 score on a non-standardized scale | Standard Deviation 2.4 |
| Active Comparator | Psychological Symptoms | Penn Alcohol Craving Scale (high worse, range 1-7) | 1.4 score on a non-standardized scale | Standard Deviation 0.2 |